CHF Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Puerto Rico
March 09 2021 - 08:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced its Aquadex SmartFlow® system is now available for the
treatment of fluid overloaded pediatric patients at the Puerto Rico
Women and Children’s Hospital in Bayamón, Puerto Rico.
Fluid overload is associated with adverse outcomes in multiple
disease states.1 Fluid removal is critical to mitigate poor
outcomes. The Aquadex™ system has a low extracorporeal value of 35
ml, a unique differentiator for pediatric patients when compared
with other fluid removal therapies that require high extracorporeal
blood volume.
“Pediatric patients require delicate treatment approaches, and
we are always looking for the safest and smartest tools available
to add to our pediatric armamentarium,” said Xamayta L.
Negroni-Balasquide, MD,MS at the Puerto Rico Women and Children’s
Hospital. “Aquadex allows us to customize the rate of fluid removal
so we can ensure hemodynamic stability. Fluid overload can quickly
create severe issues when excess fluid is not removed effectively
and efficiently. We’re thrilled to now have access to a tool that
can be tailored to our youth to help support positive
outcomes.”
“Our steadfast purpose is to improve outcomes for people
suffering from fluid overload, and that certainly means throughout
the world,” said President and CEO Nestor Jaramillo, Jr. “Our
expansion into Puerto Rico represents an important step forward in
providing a safe, predictable and effective fluid management
solution to volume overloaded patients across the globe. We’re
especially thrilled to know our therapy is now available for Puerto
Rican patients who desperately need safe and productive fluid
removal.”
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with a wholly-owned
subsidiary in Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
the Aquadex SmartFlow system to treat pediatric patients.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:Claudia Napal Drayton Chief Financial
Officer, CHF Solutions, Inc. 952-345-4205ir@chf-solutions.com
Matt Bacso, CFAGilmartin Group LLCMatt.bacso@gilmartinir.com
MEDIA:Jessica
StebingHealth+Commerce260-336-6202jstebing@healthandcommerce.com
1 Ker GL, Gangadharan S. Management of Fluid Overload in the
Pediatric ICU. Pediatric Critical Care. 2018;193-209.
Published 2018 Jul 18. doi:10.1007/978-3-319-96499-7_11
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Feb 2024 to Mar 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2023 to Mar 2024